What Is Ozanimod?

• Ozanimod is a novel, oral, selective, sphingosine 1-phosphate 1 and 5 receptor modulator in development for ulcerative colitis and Crohn’s disease. Ozanimod is also being studied for the treatment of multiple sclerosis.
• Selective binding with S1PR1 receptors is hypothesized to withhold a specific subset of lymphocytes in lymph nodes, and thus to reduce their numbers in the circulatory system. The result is a reduction of pro-inflammatory lymphocytes circulating to sites of inflammation.
• Importantly, immune surveillance is maintained.
• Ozanimod is an oral investigational medication.
• Ozanimod is an investigational compound that is not approved for any use in any country.